GENMAB AS SP.ADR/1/10DK 1 Cash Flow Conversion Efficiency

Latest as of December 2025: 0.051x

GENMAB AS SP.ADR/1/10DK 1 cash flow conversion efficiency. Based on the latest financial reports, GENMAB AS SP.ADR/1/10DK 1 (GE91) has a cash flow conversion efficiency ratio of 0.051x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€301.00 Million ≈ $351.90 Million USD) by net assets (€5.85 Billion ≈ $6.84 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of GENMAB AS SP.ADR/1/10DK 1 (2021–2025)

Cash flow conversion efficiency of GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025. This chart illustrates how GENMAB AS SP.ADR/1/10DK 1's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GENMAB AS SP.ADR/1/10DK 1 stock quote for real-time trading data and today's change.

GENMAB AS SP.ADR/1/10DK 1 Cash Flow Conversion Ratio Explained

GENMAB AS SP.ADR/1/10DK 1 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

GENMAB AS SP.ADR/1/10DK 1 Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of GENMAB AS SP.ADR/1/10DK 1 ranked by their cash flow conversion efficiency. Also see market cap of GENMAB AS SP.ADR/1/10DK 1 for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Banco de Credito e Inversiones SN:BCI	0.064x
Emera Incorporated NYSE:EMA	0.052x
Valterra Platinum Limited JSE:VAL	0.304x
HAIER SM.HME UNSP.ADR/4 F:HAI0	N/A
Bosch Limited NSE:BOSCHLTD	0.071x
Nippon Sanso Holdings Corp. NYSE:NPXYY	0.067x
POSCO Holdings Inc NYSE:PKX	0.004x
Hithink RoyalFlush Info Network SHE:300033	0.111x

Annual Cash Flow Conversion Efficiency for GENMAB AS SP.ADR/1/10DK 1 (2021–2025)

The table below shows the annual cash flow conversion efficiency of GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025. Review GE91 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€5.85 Billion ≈ $6.84 Billion	€1.19 Billion ≈ $1.39 Billion	0.203x	-4.21%
2024-12-31	€5.12 Billion ≈ $5.99 Billion	€1.08 Billion ≈ $1.27 Billion	0.212x	-9.30%
2023-12-31	€4.69 Billion ≈ $5.49 Billion	€1.10 Billion ≈ $1.28 Billion	0.233x	+62.82%
2022-12-31	€3.93 Billion ≈ $4.59 Billion	€563.05 Million ≈ $658.26 Million	0.143x	+42.85%
2021-12-31	€3.38 Billion ≈ $3.95 Billion	€339.18 Million ≈ $396.54 Million	0.100x	--

About GENMAB AS SP.ADR/1/10DK 1

F:GE91 Germany Biotechnology

Market Cap

$17.14 Billion

€14.66 Billion EUR

Market Cap Rank

#1574 Global

#352 in Germany

Share Price

€23.80

Change (1 day)

+3.48%

52-Week Range

€17.00 - €29.80

All Time High

€44.40